Recruiting
Phase 1

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

Sponsor:

AbbVie

Code:

NCT05029882

Conditions

Non-Small Cell Lung Cancer

Advanced Solid Tumors

Gastroesophageal Adenocarcinoma

Colorectal Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ABBV-400

Trifluridine/Tipiracil

Bevacizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information